Come visit us at the 28th Meeting of the Society for Neuro-Oncology (SNO) in Vancouver from November 16-19. Our team will be onsite to discuss ONC201, the Phase 3 ACTION study, and how using molecular profiling to identify patients most likely to benefit from therapy is driving advances in the treatment of glioma. On Saturday, November 18th at 12:45 PM, please join us in room 205-207 for our satellite symposium to discuss the current diagnosis, treatment strategies, and clinical trials for H3 K27M-mutant diffuse glioma.